Le Lézard
Classified in: Health, Business
Subject: CXP

TES is proud to offer an expansion of its quality services to individuals with exceptional needs in Columbus


COLUMBUS, Ohio, Sept. 17, 2018 /PRNewswire/ -- Columbus area families impacted by autism spectrum disorder, learning disabilities, and other developmental disorders will have a new, comprehensive treatment resource in their community, as Total Education Solutions (TES) expands with a new clinical location in Franklin County.  Opening in the Fall of 2018, the TES Columbus Clinic will offer a full-range of services, including speech-language therapy, occupational therapy, physical therapy, psychological/diagnostic services, and behavior services.  Through the collaboration of the leading team of passionate, experienced professionals, TES is able to provide treatment for the entirety of an individual's needs, all at one location.  TES is well-known for offering convenience, flexibility, and creative solutions to support and accommodate each family's unique circumstances.  The community is invited to our Grand Opening on Thursday, November 8th, from 4:00-6:30pm, to tour the facility, meet our providers, and participate in kid-friendly activities! Our address is: 1930 Crown Park Ct, Unit 100, Columbus, OH 43235.

About Total Education Solutions
Headquartered in South Pasadena, California, TES has grown rapidly over the years, launching multiple offices, clinics, and school-based teams across three states: California, Michigan, and Ohio.  TES was first established in the Ohio region in 2007, and has grown immensely under the leadership of Regional Director, Tawnia Novak. Since then, TES has served communities all over the state of Ohio, including Akron, Cleveland, Dayton, Cincinnati, and Columbus.  The Fairlawn clinic opened in 2011, and now includes TES Academy, which offers full-day academic curriculum and therapeutic intervention to students with exceptional needs.  

Providing Immediate Service to the Columbus Community
TES's expansion in Columbus not only meets a growing need for these types of resources in the city and surrounding areas, but also provides immediate support to the many families currently on waiting lists who are not receiving services.  The Columbus team currently provides innovative treatment in homes and schools, including compliance, consultative, and therapeutic services in line with the Ohio Department of Education, as well as community-based family supports.  The expansion of the company's services through its new clinical location signals TES' unyielding commitment to the many Ohio families in need of intervention and resources to help their children learn, grow, and exceed their potential.

For more information or to schedule a free consultation, visit www.tesidea.com or call (877)TES-IDEA.

 

SOURCE Total Education Solutions Inc


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: